OTCM
HSTC
Market cap17kUSD
Jul 21, Last price
0.00USD
1D
300.00%
1Q
-99.95%
Jan 2017
-99.56%
Name
HST Global Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.48%
Rev. gr., 5y
%
Revenues
0k
Net income
-146k
L+0.78%
CFO
-21k
L-0.61%
Profile
HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer worldwide. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life-threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 141 | 141 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (141) | (141) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (141) | (141) | |||||||
Net income | (146) 0.78% | (145) -3.93% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 98 | 76 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 438 | ||||||||
Net debt | 97 | 76 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (21) | (21) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 22 | 21 | |||||||
FCF | (17) | (17) | |||||||
| Balance | |||||||||
Cash | 2 | 190 | |||||||
Long term investments | |||||||||
Excess cash | 2 | 190 | |||||||
Stockholders' equity | (6,009) | (5,863) | |||||||
Invested Capital | 5,516 | 5,493 | |||||||
ROIC | |||||||||
ROCE | 28.54% | 38.14% | |||||||
| EV | |||||||||
Common stock shares outstanding | 5,249 | 5,249 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (141) | (141) | |||||||
EV/EBITDA | |||||||||
Interest | 4 | ||||||||
Interest/NOPBT | |||||||||